⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102374 | 1.00 | — | — | |
| SCHEMBL102107 | 1.00 | — | — | |
| SCHEMBL27149747 | 0.84 | TSHR (0.47) | — | |
| SCHEMBL571433 | 0.82 | — | — | |
| SCHEMBL4754377 | 0.82 | LMNA (0.55) | — | |
| SCHEMBL45286 | 0.82 | LMNA (0.55) | — | |
| SCHEMBL7708054 | 0.80 | LMNA (0.48) | — | |
| SCHEMBL1615126 | 0.79 | LMNA (0.42) | — | |
| SCHEMBL2301799 | 0.79 | LMNA (0.48) | — | |
| SCHEMBL14609335 | 0.79 | LMNA (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312589-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230024521-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-115003300-A | JAK inhibitors | 维玛兰生物科学公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-4034107-A1 | JAK INHIBITORS | Vimalan Biosciences, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3966209-A1 | JAK INHIBITORS | Vimalan Biosciences, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11136329-B2 | JAK inhibitors | VIMALAN BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| WO-2021062036-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20200369669-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2020227563-A1 | JAK INHIBITORS | VIMALAN BIOSCIENCES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7304071-B2 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |